2014

Solos Endoscopy Manufacturer to Conduct New Testing to Increase Sterilization Life for its MammoView® Breast Endoscopy Product Line

BOSTON, Oct. 24, 2012 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company's manufacturer of introducers, dilators and cytology retrieval kits has retained a medical testing facility in order to verify an increase in the sterilization expiration date for the disposable instruments that are part of the MammoView® Breast Endoscopy product line.  Currently, the MammoView® Breast Endoscopy disposables have a one year expiration date; the Company is now testing in order to give the products a two year expiration date.

Solos Endoscopy MammoView® Instruments are already FDA approved, however, by increasing the sterilization life to two years, the Company will be able to carry more inventory and ultimately increase sales as hospitals can be more confident in ordering larger quantities.

"Management expects that this improvement will benefit everyone, from the hospitals to the shareholders.  The Company's ability to manufacture and carry more inventory will improve our margins, and give our customers greater confidence when ordering larger quantities of our disposable product line," stated Solos Endoscopy CEO, Robert Segersten.

Solos Endoscopy retained TUV SUD America, Inc. to complete its ISO 13485 Certification and Audit on its instruments including the MammoView®.  The Company previously engaged Expert Resource to prepare the Company for the final audit.  Expert Resource will attend the final audit, and help interpret any findings.  According to Expert Resource, their consultants maintain a 100% success rate of passing the final audit on the first attempt. Solos Endoscopy has posted its updated ISO 13485 CE Mark Schedule on its website, http://solosendoscopy.com/pdf/SNDY-ISO-13485-CE-Mark-Project-Schedule-October-2012.pdf.

Solos Endoscopy management is aware that the Depository Trust Company ("DTC") has recently imposed a deposit transaction restriction or Deposit Chill on new deposits of the Company's stock through DTC.  Solos Endoscopy has submitted its objection to DTC and its securities attorney is currently working with DTC to provide them with all the documentation they have requested.  If you have specific questions regarding your individual deposit we suggest you contact your licensed financial advisor.   Solos Endoscopy's President's Letter and CE Mark Schedule are posted on its website www.solosendoscopy.com.  The Company is in the process of completing its 3rd Quarter Financial statement which will be posted on OTC Markets.   

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

For more information on TUV SUD America visit www.tuvamerica.com.  

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact:
Solos Endoscopy, Inc.
(617) 360-9719

 

SOURCE Solos Endoscopy, Inc.



RELATED LINKS
http://www.solosendoscopy.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.